Nurse Practitioner in Clay City, KY Accepting Medicare
6 Nurse Practitioner nurses found. Showing 1 - 6
 Mrs. Gari Michelle Kiser, APRN Nurse Practitioner - Psych/Mental Health Medicare: Accepting Medicare Assignments Practice Location: 108 12th St, Clay City, KY 40312 Phone: 606-663-9011 |
Felicia Estes, APRN, FNP-BC Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 749 Irvine Rd, Clay City, KY 40312 Phone: 606-663-2153 |
Mrs. Sandra Dee Mccoy, APRN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 749 Irvine Rd, Clay City, KY 40312 Phone: 606-663-2153 Fax: 606-663-7966 |
Leslie Rae Cordial, APRN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 98 River St, Clay City, KY 40312 Phone: 606-663-7788 Fax: 606-663-7785 |
Dorrita Mullins, ARNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 98 River Street, Clay City, KY 40312 Phone: 606-663-7788 Fax: 606-663-7785 |
Christy R Slone, Nurse Practitioner - Acute Care Medicare: Accepting Medicare Assignments Practice Location: 98 River St, Clay City, KY 40312 Phone: 606-481-0152 |
News Archive
NMR technique reveals the cause of synergistic toxicity in nanomaterials
A new study finds reason for caution - a clear emergence of toxicity - in nanomaterial product formulations, but it also provides an early testing technique that could help the industry continue to move forward.
Combination of chemotherapy and immune checkpoint inhibitors shows promise in NSCLC patients with untreated brain metastases
Treatment with atezolizumab plus carboplatin and pemetrexed was safe and yielded promising brain progression-free survival in patients with nonsquamous non-small cell lung cancer with untreated and asymptomatic brain metastases.
Novelos continues NOV-002 Phase 3 combination trial for lung cancer
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting Pfizer Inc. has announced that it has decided to discontinue the late-stage study of its lung cancer candidate figitumumab (CP-751,871) while Novelos' pivotal Phase 3 trial, with a primary efficacy endpoint of improvement in median overall survival, continues across approximately 12 countries and 100 clinical sites.
Angiotech receives favourable patent decision from New Zealand
Angiotech Pharmaceuticals, Inc. announced today that it received a favourable decision from the Intellectual Property Office of New Zealand regarding an attempt by Johnson & Johnson's subsidiary, Conor Medsystems Inc. ("Conor") to revoke Angiotech's New Zealand Patent 523799, which pertains to compositions comprising a polymer and paclitaxel, as well as, generally, to paclitaxel-eluting stents.
› Verified 5 days ago